Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes

Diabetes Care

Volumn 28, Issue 5, 2005, Pages 995-1000

  Cook, Michael N ^a   Girman, Cynthia J ^a   Stein, Peter P ^a   Alexander, Charles M ^a   Holman, Rury R ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; METFORMIN; SULFONYLUREA;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ELECTRONIC MEDICAL RECORD; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PRIMARY MEDICAL CARE; SEX RATIO; SMOKING; UNITED KINGDOM;

ADULT; AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; RETROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS; TREATMENT FAILURE;

EID: 18144377715     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.28.5.995     Document Type: Article

References (27)

1. Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047-1053, 2004
2. Hogan P, Dall T, Nikolov P, the American Diabetes Association: Economic costs of diabetes in the U.S. in 2002. Diabetes Care 26:917-932, 2003
3. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
4. Diabetes Control and Complications Trial (DCCT) Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes mellitus. N Engl J Med 329:977-980, 1993
5. American Diabetes Association: Standards of medical care of diabetes. Diabetes Care 27 (Suppl. 1):S15-S35, 2004
6. McIntosh A: Clinical Guidelines and Evidence Review for Type 2 Diabetes: Blood Glucose Management. Sheffield, U.K., University of Sheffield Press, 2001
7. U.K. Prospective Diabetes Study Group: UK Prospective Diabetes Study 16. Overview of six years' therapy of type 2 diabetes: a progressive disease. Diabetes 44: 1249-1258, 1995
8. Wright A, Burden ACF, Paisey RB, Cull CA, Holman RR: Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care 25:330-336, 2002
9. Wallace TM, Matthews DR: Coefficient of failure: a methodology for examining longitudinal β-cell function in type 2 diabetes. Diabet Med 19:465-469, 2002
10. Inzucchi SE: Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 287:360-372, 2002
11. Turner RC, Cull CA, Frighi V, Holman RR: Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes: progressive requirement for multiple therapies (UKPDS 49). JAMA 281:2005-2012, 1999
12. Matthews DR, Cull CA, Straon IM, Holman RR, Turner RC: UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. Diabet Med 15:297-303, 1998
13. Pontiroli AE: Secondary failure of oral hypoglycaemic agents: frequency, possible causes, and management. Diabetes Metab Rev 10:31-43, 1994
14. Edwards G: Long-Term Combination Therapy With Pioglitazone Plus Metformin for Type 2 Diabetes: A Randomized Comparative Study With Glicazide Plus Metformin (Abstract). New Orleans, LA, American Diabetes Association Annual Meeting, 2003
15. Groop LC, Pelkonen R, Koskimies S: Secondary failure to treatment with oral antidiabetic agents in non-insulin-dependent diabetes. Diabetes Care 9:129-133, 1986
16. Hanefeld MK, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH, the Quartet Study Group: One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 27:141-147, 2004
17. Schernthaner G: The Efficacy of Pioglitazone Compared To Metformin in Drug-Naïve Patients With Type 2 Diabetes (Abstract). New Orleans, LA, American Diabetes Association Annual Meeting, 2003
18. St. John-Sutton M, Rendell M, Dandona P, Dole JF, Murphy K, Patwardham R, Patel J, Freed M: A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 25:2058-2064, 2002
19. Tan MH: Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control and lipid profiles in patients with type 2 diabetes. Diabet Med 21:859-866, 2004
20. Wofford M: Glyburide-Metformin Tablets Versus Pioglitazone as First-Line Treatment in Type 2 Diabetes: Efficacy and Safety (Abstract). New Orleans, LA, American Diabetes Association Annual Meeting, 2003
21. Brown JB, Nichols GA: Slow response to loss of glycemic control in type 2 diabetes mellitus. Am J Managed Care 9:213-217, 2003
22. Donnan PT, Steinke DT, Newton RW, Morris AD, for the DARTS/MEMO Collaboration: Changes in treatment after the start of oral hypoglycemic therapy in type 2 diabetes: a population-based study. Diabet Med 19:606-610, 2002
23. Boccuzzi SJ, Wogen J, Fox J, Sung JCY, Shah AB, Kim J: Utilization of oral hypoglycemic agents in a drug-insured U.S. population. Diabetes Care 24:1411-1415, 2001
24. Brown JB, Nichols GA, Perry A: The burden of treatment failure in type 2 diabetes. Diabetes Care 27:1535-1540, 2004
25. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865, 1998
26. Lawson DH, Sherman V, Hollowell J: The General Practice Research Database. Q J Med 91:445-452, 1998
27. Davis S, Rietbrock S, Rubino A, Shah AD, Williams T, Martinez C: Auditing the: quality of data in the General Practice Research Database (Abstract). Pharmacoepidemiol Drug Saf 12:S61, 2003